Pivotal-Point Tracking CryoPort (CYRX): Specialist in Cold Chain Logistics for the Medicine of Tomorrow Delivers with 14% Revenue Increase
Reading Time: 1 minute
CryoPort is a provider of temperature-controlled supply chain solutions, biostorage, and cryo-systems for the biopharma industry. On November 5, the company reported a 14% increase in revenue for Q3 2026 to $50.2 million (consensus: $48.7 million) and raised its annual forecast to $197 to $199 million. The adjusted EBITDA turned significantly positive at $1.1 million (previous year: -$0.6 million), while the net loss per share was $0.25. With $393.1 million in cash, the company now supports 23 commercially approved therapies and a record 788 clinical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

